智翔金泰预计2025年营业收入同比大幅增长595.96%至733.62%

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (referred to as "Zhixiang Jintai") expects significant revenue growth for the year 2025, while still projecting a net loss, albeit with a reduced loss compared to the previous year [1][2]. Financial Performance - The company forecasts a revenue of between 209 million to 251 million yuan for 2025, representing an increase of 179 million to 221 million yuan year-on-year, which translates to a substantial growth of 595.96% to 733.62% [1]. - The projected net loss attributable to the parent company for 2025 is estimated to be between 481 million to 587 million yuan, which is a year-on-year reduction in loss of 26.32% to 39.71% [1]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be between 524 million to 630 million yuan, with a year-on-year loss reduction of 21.62% to 34.90% [1]. Research and Development - The company anticipates R&D expenses for 2025 to be between 425 million to 520 million yuan, reflecting a decrease of 14.77% to 30.27% compared to the previous year [1]. - The company maintains a high level of R&D investment as multiple products enter clinical research and core products reach critical clinical trial phases [2]. - The absence of share-based payment expenses in 2025, due to the completion of the stock incentive plan for the core team in 2024, contributes to the reduction in overall expenses [2].